Unichem Lab gets USFDA nod for Quetiapine extended-release tablets by admin- Tuesday, August 16th, 2022 03:22:54 PM
Unichem Laboratories received ANDA popularity of its Quetiapine Extended-Release Tablets USP, 50 mg, a hundred and fifty mg, 200 mg, three hundred mg, and
400 mg from the USA Food and Drug Administration (USFDA) to marketplace a usual model of SEROQUEL XR (Quetiapine) Tablet, Extended Release, 50 mg, a hundred and fifty mg, two hundred mg, three hundred mg, and four hundred mg of AstraZeneca Pharmaceuticals LP.
Quetiapine Extended-Release Tablets are indicated for the treatment of Schizophrenia, Bipolar disease and adjunctive treatment of Major Depressive Disorder (MDD). The product could be commercialized from Unichem’s Goa Plant.